Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine Combinations in AML and MDS
NCT02190695Phase 2Completed
- Sponsor
- Fox Chase Cancer Center
- Start
- Apr 2013
- Primary completion
- Jun 2018
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of carboplatin, arsenic trioxide in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), sponsored by Fox Chase Cancer Center. Started Apr 2013; status: completed.
02
Drugs
carboplatinarsenic trioxide
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT02190695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02190695.